12th Feb 2025 09:51
Celadon Pharmaceuticals PLC - London-based pharmaceutical company, focused on cannabis-based medicines - Says it has received the final GBP103,000 from its GBP1.0 million draw down request under its committed credit facility. Says it has also received a GBP389,000 tax credit from a 2022 research & development claim. The company says it will continue to explore "further capital opportunities".
Current stock price: 20.51 pence, up 14% in London on Wednesday morning
12-month change: down 82%
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Celadon Pharmaceuticals